While the combination benefit between SGLT-2 diabetes treatment and other treatments is expected to be applied from April, the two-drug regimen between SGLT2 and DPP4, which was omitted from the current discussion, is also expected to be reviewed. It is expected that if the SGLT2+DDP4 complex is applied for reimbursement, it will naturally be sorted out through discussion. According to the industry on the 23rd, some SGLT2+DPP4 combinations have applied for reimbursement to the HIRA. It is known that AstraZeneca's 'Qtern', Boehringer Ingelheim's Esglito, and LG Chem's SGLT-2 inhibitory antidiabetic drugs (from left: Forxiga, Jardiance, Xigduo XR, Jardiance Duo) applied for benefits. MSD's Steglujan is also expected to